APA (7th ed.) Citation

Moneglia, M., Santangelo, A., Burian, I., Gragnani, L., Elisa, F., Quargnolo, M., . . . Zignego, A. (2017). Second generation direct-acting antiviral (DAAs) Treatment on HCV+ patients: Patient reported outcomes (PROs) and psychiatric symptoms in a real world setting sample. European Psychiatry, 41, S316. https://doi.org/10.1016/j.eurpsy.2017.02.230

Chicago Style (17th ed.) Citation

Moneglia, M., A. Santangelo, I. Burian, L. Gragnani, F. Elisa, M. Quargnolo, S. Pallanti, and A.L Zignego. "Second Generation Direct-acting Antiviral (DAAs) Treatment on HCV+ Patients: Patient Reported Outcomes (PROs) and Psychiatric Symptoms in a Real World Setting Sample." European Psychiatry 41 (2017): S316. https://doi.org/10.1016/j.eurpsy.2017.02.230.

MLA (9th ed.) Citation

Moneglia, M., et al. "Second Generation Direct-acting Antiviral (DAAs) Treatment on HCV+ Patients: Patient Reported Outcomes (PROs) and Psychiatric Symptoms in a Real World Setting Sample." European Psychiatry, vol. 41, 2017, p. S316, https://doi.org/10.1016/j.eurpsy.2017.02.230.